The FDA has decided to delay its decision on Spectrum Pharmaceuticals' (SPPI) Rolontis, which was due on October 24, as the regulatory agency has been unable to conduct inspection of the drug substance manufacturing facility due to COVID-19 related travel curbs.
from RTT - Biotech https://ift.tt/31IMGXI
via IFTTT
No comments:
Post a Comment